What Is CytomX Therapeutics, Inc. (CTMX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, CytomX Therapeutics, Inc.'s intrinsic value is estimated at $1.89. Trading at its current price of $3.66, the valuation engine raises significant caution: 11 of 12 models flag downside risk, projecting an average implied return of -48.3%. Notably, PWERM sees the most upside at +4.7% (fair value: $3.83), while Bayesian DCF is the most conservative at -87.9% ($0.44). The spread between these extremes — +92.6% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About CTMX?
12 of 13 models are currently active for CTMX. Of these, 1 model suggests upside while 11 models suggest overvaluation. The Bayesian DCF estimates CTMX's intrinsic value at $0.44, implying -87.9% downside from the current price. See which stocks rank higher →
How Does CTMX Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, CTMX ranks #49 by Quality of Company score. CirclFi's QOC score of 7.5/10 evaluates 32 fundamental signals. A score of 7.5 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
CytomX Therapeutics, Inc.'s positioning within the Pharmaceutical Preparations segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.
Is CTMX a Value Trap?
CirclFi's Value Trap algorithm assigns CTMX a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for CytomX Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, CytomX Therapeutics, Inc. earns a quality score of 7.5/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +92.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CTMX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CTMX's 12 active models, average confidence is 37%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad